JPS322220B1 - - Google Patents
Info
- Publication number
- JPS322220B1 JPS322220B1 JP2601554A JP2601554A JPS322220B1 JP S322220 B1 JPS322220 B1 JP S322220B1 JP 2601554 A JP2601554 A JP 2601554A JP 2601554 A JP2601554 A JP 2601554A JP S322220 B1 JPS322220 B1 JP S322220B1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2601554A JPS322220B1 (zh) | 1954-11-30 | 1954-11-30 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2601554A JPS322220B1 (zh) | 1954-11-30 | 1954-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS322220B1 true JPS322220B1 (zh) | 1957-04-11 |
Family
ID=45422381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2601554A Pending JPS322220B1 (zh) | 1954-11-30 | 1954-11-30 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS322220B1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005070893A3 (en) * | 2004-01-09 | 2007-01-18 | Corcept Therapeutics Inc | Azadecalin glucocorticoid receptor modulators |
US10047082B2 (en) | 2013-11-25 | 2018-08-14 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US11058670B2 (en) | 2019-02-22 | 2021-07-13 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
-
1954
- 1954-11-30 JP JP2601554A patent/JPS322220B1/ja active Pending
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005070893A3 (en) * | 2004-01-09 | 2007-01-18 | Corcept Therapeutics Inc | Azadecalin glucocorticoid receptor modulators |
JP2007517894A (ja) * | 2004-01-09 | 2007-07-05 | コーセプト セラピューティクス, インコーポレイテッド | アザデカリン糖質コルチコイド受容体モジュレーター |
US7678813B2 (en) | 2004-01-09 | 2010-03-16 | Corcept Therapeutics, Inc. | Azadecalin Glucocorticoid receptor modulators |
JP4851345B2 (ja) * | 2004-01-09 | 2012-01-11 | コーセプト セラピューティクス, インコーポレイテッド | アザデカリン糖質コルチコイド受容体モジュレーター |
US8324203B2 (en) | 2004-01-09 | 2012-12-04 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
US11560379B2 (en) | 2013-11-25 | 2023-01-24 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10323034B2 (en) | 2013-11-25 | 2019-06-18 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10787449B2 (en) | 2013-11-25 | 2020-09-29 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US11370789B2 (en) | 2013-11-25 | 2022-06-28 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US10047082B2 (en) | 2013-11-25 | 2018-08-14 | Corcept Therapeutics, Inc. | Octahydro fused azadecalin glucocorticoid receptor modulators |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11058670B2 (en) | 2019-02-22 | 2021-07-13 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11590113B2 (en) | 2019-02-22 | 2023-02-28 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11684612B2 (en) | 2019-02-22 | 2023-06-27 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |